{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T02:00:48Z","timestamp":1794880848431,"version":"4.9.1"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Synapse damage and loss are fundamental to the pathophysiology of Alzheimer\u2019s disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges of forging new clinical development approaches for AD therapeutics that can demonstrate reduction of synapse damage or loss.<\/jats:p>\n                    <jats:p>\n                      The key points of this review include the following:\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Synapse loss is a downstream effect of amyloidosis, tauopathy, inflammation, and other mechanisms occurring in AD.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Synapse loss correlates most strongly with cognitive decline in AD because synaptic function underlies cognitive performance.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Compounds that halt or reduce synapse damage or loss have a strong rationale as treatments of AD.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Biomarkers that measure synapse degeneration or loss in patients will facilitate clinical development of such drugs.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The ability of methods to sensitively measure synapse density in the brain of a living patient through synaptic vesicle glycoprotein 2A (SV2A) positron emission tomography (PET) imaging, concentrations of synaptic proteins (e.g., neurogranin or synaptotagmin) in the cerebrospinal fluid (CSF), or functional imaging techniques such as quantitative electroencephalography (qEEG) provides a compelling case to use these types of measurements as biomarkers that quantify synapse damage or loss in clinical trials in AD.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A number of emerging biomarkers are able to measure synapse injury and loss in the brain and may correlate with cognitive function in AD. These biomarkers hold promise both for use in diagnostics and in the measurement of therapeutic successes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-020-00588-4","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T09:08:38Z","timestamp":1583140118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":287,"title":["The clinical promise of biomarkers of synapse damage or loss in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"12","author":[{"name":"the Synaptic Health Endpoints Working Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00ed","family":"Colom-Cadena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Spires-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Caggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"DeKosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Fillit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lon S.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grundman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"van Dyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Izzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"issue":"1","key":"588_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","volume":"18","author":"E Nichols","year":"2019","unstructured":"Nichols E, Szoeke CEI, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):88\u2013106.","journal-title":"Lancet Neurol"},{"key":"588_CR2","doi-asserted-by":"crossref","unstructured":"Association A. 2018 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement. Elsevier; 2018; 14(3):367\u2013429 [cited 2018 Jun 18]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1552526018300414.","DOI":"10.1016\/j.jalz.2018.02.001"},{"key":"588_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2377-9-7","volume":"9","author":"CM Persson","year":"2009","unstructured":"Persson CM, Wallin AK, Levander S, Minthon L. Changes in cognitive domains during three years in patients with Alzheimer\u2019s disease treated with donepezil. BMC Neurol. 2009;9:7 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19208247.","journal-title":"BMC Neurol"},{"issue":"1","key":"588_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jalz.2009.05.665","volume":"6","author":"K Ito","year":"2010","unstructured":"Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T, et al. Disease progression meta-analysis model in Alzheimer\u2019s disease. Alzheimers Dement. 2010;6(1):39\u201353 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19592311.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"588_CR5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3233\/JAD-161118","volume":"57","author":"R Kandimalla","year":"2017","unstructured":"Kandimalla R, Reddy PH. Therapeutics of neurotransmitters in Alzheimer\u2019s disease. J Alzheimers Dis. 2017;57(4):1049\u201369 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28211810.","journal-title":"J Alzheimers Dis"},{"issue":"15","key":"588_CR6","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1056\/NEJMe1903193","volume":"380","author":"DS Knopman","year":"2019","unstructured":"Knopman DS. Lowering of amyloid-beta by \u03b2-secretase inhibitors - some informative failures. N Engl J Med. 2019;380(15):1476\u20138 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30970194.","journal-title":"N Engl J Med"},{"issue":"4","key":"588_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","volume":"83","author":"CH van Dyck","year":"2018","unstructured":"van Dyck CH. Anti-amyloid-\u03b2 monoclonal antibodies for Alzheimer\u2019s disease: pitfalls and promise. Biol Psychiatry. 2018;83(4):311\u20139 Available from: https:\/\/doi.org\/10.1016\/j.biopsych.2017.08.010.","journal-title":"Biol Psychiatry"},{"key":"588_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","volume":"129","author":"KL Viola","year":"2015","unstructured":"Viola KL, Klein WL. Amyloid beta oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015;129:183\u2013206.","journal-title":"Acta Neuropathol"},{"key":"588_CR9","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195074017.001.0001","volume-title":"Histology of the nervous system of man and vertebrates, volume 1","author":"SR y Cajal","year":"1995","unstructured":"y Cajal SR. Histology of the nervous system of man and vertebrates, volume 1. New York: Oxford University Press; 1995."},{"key":"588_CR10","volume-title":"The organization of behavior: a neuropsychological theory [Internet]","author":"D Hebb","year":"1949","unstructured":"Hebb D. The organization of behavior: a neuropsychological theory [Internet]. New York: Wiley; 1949. Available from: http:\/\/doi.wiley.com\/10.1002\/sce.37303405110."},{"issue":"5544","key":"588_CR11","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1126\/science.1067020","volume":"294","author":"ER Kandel","year":"2001","unstructured":"Kandel ER. The molecular biology of memory storage: a dialogue between genes and synapses. Science. 2001;294(5544):1030\u20138 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11691980.","journal-title":"Science"},{"issue":"2","key":"588_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1113\/jphysiol.1973.sp010273","volume":"232","author":"TV Bliss","year":"1973","unstructured":"Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol. 1973;232(2):331\u201356 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/4727084.","journal-title":"J Physiol"},{"issue":"1633","key":"588_CR13","doi-asserted-by":"publisher","first-page":"20130288","DOI":"10.1098\/rstb.2013.0288","volume":"369","author":"T Takeuchi","year":"2014","unstructured":"Takeuchi T, Duszkiewicz AJ, RGM M. The synaptic plasticity and memory hypothesis: encoding, storage and persistence. Philos Trans R Soc Lond B Biol Sci. 2014;369(1633):20130288 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24298167.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"6","key":"588_CR14","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jalz.2015.12.005","volume":"12","author":"MC De Wilde","year":"2016","unstructured":"De Wilde MC, Overk CR, Sijben JW, Masliah E. Meta-analysis of synaptic pathology in Alzheimer\u2019s disease reveals selective molecular vesicular machinery vulnerability. Alzheimer\u2019s Dement. 2016;12(6):633\u201344. Available from:. https:\/\/doi.org\/10.1016\/j.jalz.2015.12.005.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"4","key":"588_CR15","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.neuron.2014.05.004","volume":"82","author":"TL Spires-Jones","year":"2014","unstructured":"Spires-Jones TL, Hyman B. The intersection of amyloid beta and tau at synapses in Alzheimer\u2019s disease. Neuron. 2014;82(4):756\u201371. Available from:. https:\/\/doi.org\/10.1016\/j.neuron.2014.05.004.","journal-title":"Neuron"},{"issue":"5","key":"588_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol. 1990;27(5):457\u201364 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2360787.","journal-title":"Ann Neurol"},{"issue":"5","key":"588_CR17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/BF01273157","volume":"103","author":"K Blennow","year":"1996","unstructured":"Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P. Synaptic pathology in Alzheimer\u2019s disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm. 1996;103(5):603\u201318 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8811505.","journal-title":"J Neural Transm"},{"issue":"4","key":"588_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1006\/neur.1996.0056","volume":"5","author":"ST DeKosky","year":"1996","unstructured":"DeKosky ST, Scheff SW, Styren SD. Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration. 1996;5(4):417\u201321 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9117556.","journal-title":"Neurodegeneration"},{"issue":"4","key":"588_CR19","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572\u201380 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1789684.","journal-title":"Ann Neurol"},{"issue":"8","key":"588_CR20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.neurobiolaging.2003.08.002","volume":"24","author":"SW Scheff","year":"2003","unstructured":"Scheff SW, Price DA. Synaptic pathology in Alzheimer\u2019s disease: a review of ultrastructural studies. Neurobiol Aging. 2003;24(8):1029\u201346 [cited 2014 May 13]. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458003001805.","journal-title":"Neurobiol Aging"},{"issue":"3","key":"588_CR21","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3233\/JAD-141518","volume":"43","author":"SW Scheff","year":"2015","unstructured":"Scheff SW, Price DA, Ansari MA, Roberts KN, Schmitt FA, Ikonomovic MD, et al. Synaptic change in the posterior cingulate gyrus in the progression of Alzheimer\u2019s disease. J Alzheimers Dis. 2015;43(3):1073\u201390 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24529280.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"588_CR22","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3233\/JAD-122353","volume":"35","author":"SW Scheff","year":"2013","unstructured":"Scheff SW, Price DA, Schmitt FA, Roberts KN, Ikonomovic MD, Mufson EJ. Synapse stability in the precuneus early in the progression of Alzheimer\u2019s disease. J Alzheimers Dis. 2013;35(3):599\u2013609 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23478309.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"588_CR23","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.neurobiolaging.2007.04.010","volume":"29","author":"A Kashani","year":"2008","unstructured":"Kashani A, Lepicard E, Poirel O, Videau C, David JP, Fallet-Bianco C, et al. Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease. Neurobiol Aging. 2008;29(11):1619\u201330 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17531353.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"588_CR24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/brain\/awx352","volume":"141","author":"E Bereczki","year":"2018","unstructured":"Bereczki E, Branca RM, Francis PT, Pereira JB, Baek J-H, Hortob\u00e1gyi T, et al. Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. Brain. 2018;141(2):582\u201395 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29324989.","journal-title":"Brain"},{"issue":"11","key":"588_CR25","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jalz.2016.04.005","volume":"12","author":"E Bereczki","year":"2016","unstructured":"Bereczki E, Francis PT, Howlett D, Pereira JB, H\u00f6glund K, Bogstedt A, et al. Synaptic proteins predict cognitive decline in Alzheimer\u2019s disease and Lewy body dementia. Alzheimers Dement. 2016;12(11):1149\u201358 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27224930.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"588_CR26","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.neurobiolaging.2014.06.015","volume":"35","author":"DR Whitfield","year":"2014","unstructured":"Whitfield DR, Vallortigara J, Alghamdi A, Howlett D, Hortob\u00e1gyi T, Johnson M, et al. Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer\u2019s disease: association with cognitive impairment. Neurobiol Aging. 2014;35(12):2836\u201344 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25104558.","journal-title":"Neurobiol Aging"},{"issue":"10043","key":"588_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer\u2019s disease. Lancet. 2016;388(10043):505\u201317 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26921134.","journal-title":"Lancet"},{"issue":"1","key":"588_CR28","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22229116.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"588_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 2012;8(1):1\u201313 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22265587.","journal-title":"Alzheimers Dement"},{"issue":"Pt 7","key":"588_CR30","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1093\/brain\/aws127","volume":"135","author":"RM Koffie","year":"2012","unstructured":"Koffie RM, Hashimoto T, Tai H-C, Kay KR, Serrano-Pozo A, Joyner D, et al. Apolipoprotein E4 effects in Alzheimer\u2019s disease are mediated by synaptotoxic oligomeric amyloid-\u03b2. Brain. 2012;135(Pt 7):2155\u201368 [cited 2014 May 1]. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3381721&tool=pmcentrez&rendertype=abstract.","journal-title":"Brain"},{"issue":"10","key":"588_CR31","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1073\/pnas.0811698106","volume":"106","author":"RM Koffie","year":"2009","unstructured":"Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A. 2009;106(10):4012\u20137 Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=2656196&tool=pmcentrez&rendertype=abstract.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"31","key":"588_CR32","doi-asserted-by":"publisher","first-page":"7278","DOI":"10.1523\/JNEUROSCI.1879-05.2005","volume":"25","author":"TL Spires","year":"2005","unstructured":"Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25(31):7278\u201387 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16079410.","journal-title":"J Neurosci"},{"key":"588_CR33","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1111\/ejn.13442","volume":"44","author":"RJ Jackson","year":"2016","unstructured":"Jackson RJ, Rudinskiy N, Herrmann AG, Croft S, Kim JM, Petrova V, et al. Human tau increases amyloid \u03b2 plaque size but not amyloid \u03b2-mediated synapse loss in a novel mouse model of Alzheimer\u2019s disease. Eur J Neurosci. 2016;44:3056\u201366 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27748574.","journal-title":"Eur J Neurosci"},{"issue":"3","key":"588_CR34","doi-asserted-by":"publisher","first-page":"e201800028","DOI":"10.26508\/lsa.201800028","volume":"1","author":"Y Yu","year":"2018","unstructured":"Yu Y, Jans DC, Winblad B, Tjernberg LO, Schedin-Weiss S. Neuronal A\u03b242 is enriched in small vesicles at the presynaptic side of synapses. Life Sci Alliance. 2018;1(3):e201800028 Available from: http:\/\/www.life-science-alliance.org\/lookup\/doi\/10.26508\/lsa.201800028.","journal-title":"Life Sci Alliance"},{"issue":"5","key":"588_CR35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.neuron.2010.04.031","volume":"66","author":"KH Ashe","year":"2010","unstructured":"Ashe KH, Zahs KR. Probing the biology of Alzheimer\u2019s disease in mice. Neuron. 2010;66(5):631\u201345 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20547123.","journal-title":"Neuron"},{"issue":"17","key":"588_CR36","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.15252\/embj.201797397","volume":"36","author":"H Sasaguri","year":"2017","unstructured":"Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, et al. APP mouse models for Alzheimer\u2019s disease preclinical studies. EMBO J. 2017;36(17):2473\u201387 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28768718.","journal-title":"EMBO J"},{"issue":"5","key":"588_CR37","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nn.3697","volume":"17","author":"T Saito","year":"2014","unstructured":"Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, et al. Single App knock-in mouse models of Alzheimer\u2019s disease. Nat Neurosci. 2014;17(5):661\u20133 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24728269.","journal-title":"Nat Neurosci"},{"issue":"5","key":"588_CR38","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362\u201381 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22487856.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"588_CR39","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/BF00293464","volume":"81","author":"E Masliah","year":"1991","unstructured":"Masliah E, Hansen L, Albright T, Mallory M, Terry RD. Immunoelectron microscopic study of synaptic pathology in Alzheimer\u2019s disease. Acta Neuropathol. 1991;81(4):428\u201333 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1903014.","journal-title":"Acta Neuropathol"},{"key":"588_CR40","doi-asserted-by":"crossref","unstructured":"Cline EN, Bicca MA, Viola KL, Klein WL. The amyloid-\u03b2 oligomer hypothesis: beginning of the third decade. J Alzheimers Dis. 2018;64:S567\u2013610. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29843241.","DOI":"10.3233\/JAD-179941"},{"issue":"11","key":"588_CR41","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","volume":"95","author":"MP Lambert","year":"1998","unstructured":"Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95(11):6448\u201353 Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=27787&tool=pmcentrez&rendertype=abstract.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6880","key":"588_CR42","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/416535a","volume":"416","author":"DM Walsh","year":"2002","unstructured":"Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid \u03b2 protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416(6880):535\u20139 [cited 2018 Jul 9]. Available from: http:\/\/www.nature.com\/articles\/416535a.","journal-title":"Nature"},{"issue":"1","key":"588_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nn1372","volume":"8","author":"JP Cleary","year":"2005","unstructured":"Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8(1):79\u201384 [cited 2014 May 2]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15608634.","journal-title":"Nat Neurosci"},{"issue":"7082","key":"588_CR44","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nature04533","volume":"440","author":"S Lesn\u00e9","year":"2006","unstructured":"Lesn\u00e9 S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440(7082):352\u20137 [cited 2014 Apr 29]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16541076.","journal-title":"Nature"},{"issue":"8","key":"588_CR45","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","volume":"14","author":"GM Shankar","year":"2008","unstructured":"Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837\u201342 [cited 2014 May 21]. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=2772133&tool=pmcentrez&rendertype=abstract.","journal-title":"Nat Med"},{"issue":"Pt 5","key":"588_CR46","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/brain\/awt062","volume":"136","author":"SE Lesn\u00e9","year":"2013","unstructured":"Lesn\u00e9 SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, et al. Brain amyloid-\u03b2 oligomers in ageing and Alzheimer\u2019s disease. Brain. 2013;136(Pt 5):1383\u201398 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23576130.","journal-title":"Brain"},{"issue":"1","key":"588_CR47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ana.23748","volume":"73","author":"TJ Esparza","year":"2013","unstructured":"Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, et al. Amyloid-\u03b2 oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol. 2013;73(1):104\u201319 [cited 2014 Apr 28]. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3563737&tool=pmcentrez&rendertype=abstract.","journal-title":"Ann Neurol"},{"issue":"8","key":"588_CR48","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1093\/brain\/awt171","volume":"136","author":"BG Perez-Nievas","year":"2013","unstructured":"Perez-Nievas BG, Stein TD, Tai H-C, Dols-Icardo O, Scotton TC, Barroeta-Espar I, et al. Dissecting phenotypic traits linked to human resilience to Alzheimer\u2019s pathology. Brain. 2013;136(8):2510\u201326 Available from: https:\/\/academic.oup.com\/brain\/article-lookup\/doi\/10.1093\/brain\/awt171.","journal-title":"Brain"},{"issue":"4","key":"588_CR49","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1523\/JNEUROSCI.3501-06.2007","volume":"27","author":"PN Lacor","year":"2007","unstructured":"Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer\u2019s disease. J Neurosci. 2007;27(4):796\u2013807 [cited 2014 May 2]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17251419.","journal-title":"J Neurosci"},{"issue":"49","key":"588_CR50","doi-asserted-by":"publisher","first-page":"11947","DOI":"10.1523\/JNEUROSCI.2009-17.2017","volume":"37","author":"Z Wang","year":"2017","unstructured":"Wang Z, Jackson RJ, Hong W, Taylor WM, Corbett GT, Moreno A, et al. Human brain-derived A\u03b2 oligomers bind to synapses and disrupt synaptic activity in a manner that requires APP. J Neurosci. 2017;37(49):11947\u201366 Available from: http:\/\/www.biorxiv.org\/content\/early\/2017\/05\/09\/135673.","journal-title":"J Neurosci"},{"issue":"2","key":"588_CR51","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.mcn.2007.02.006","volume":"35","author":"B Calabrese","year":"2007","unstructured":"Calabrese B, Shaked GM, Tabarean IV, Braga J, Koo EH, Halpain S. Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein. Mol Cell Neurosci. 2007;35(2):183\u201393 [cited 2014 Apr 29]. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=2268524&tool=pmcentrez&rendertype=abstract.","journal-title":"Mol Cell Neurosci"},{"issue":"3","key":"588_CR52","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","volume":"155","author":"L-F Lue","year":"1999","unstructured":"Lue L-F, Kuo Y-M, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid \u03b2 peptide concentration as a predictor of synaptic change in Alzheimer\u2019s disease. Am J Pathol. 1999;155(3):853\u201362 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000294401065184X.","journal-title":"Am J Pathol"},{"issue":"4","key":"588_CR53","doi-asserted-by":"publisher","first-page":"825.e1","DOI":"10.1016\/j.neurobiolaging.2011.05.003","volume":"33","author":"F Bao","year":"2012","unstructured":"Bao F, Wicklund L, Lacor PN, Klein WL, Nordberg A, Marutle A. Different \u03b2-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging. 2012;33(4):825.e1\u201313 [cited 2014 May 15]. Available from: https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.05.003.","journal-title":"Neurobiol Aging"},{"issue":"3","key":"588_CR54","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3233\/JAD-160007","volume":"53","author":"EK Pickett","year":"2016","unstructured":"Pickett EK, Koffie RM, Wegmann S, Henstridge CM, Herrmann AG, Colom-Cadena M, et al. Non-fibrillar oligomeric amyloid-\u03b2 within synapses. J Alzheimers Dis. 2016;53(3):787\u2013800.","journal-title":"J Alzheimers Dis"},{"issue":"6152","key":"588_CR55","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1126\/science.1244166","volume":"341","author":"I Benilova","year":"2013","unstructured":"Benilova I, De Strooper B. Neuroscience. Promiscuous Alzheimer\u2019s amyloid: yet another partner. Science. 2013;341(6152):1354\u20135 [cited 2014 mMay 21]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24052299.","journal-title":"Science"},{"issue":"Pt 2","key":"588_CR56","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/brain\/awv356","volume":"139","author":"LT Haas","year":"2016","unstructured":"Haas LT, Salazar SV, Kostylev MA, Um JW, Kaufman AC, Strittmatter SM. Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer\u2019s disease. Brain. 2016;139(Pt 2):526\u201346 [cited 2018 Oct 18]. Available from: https:\/\/academic.oup.com\/brain\/article-lookup\/doi\/10.1093\/brain\/awv356.","journal-title":"Brain"},{"issue":"27","key":"588_CR57","doi-asserted-by":"publisher","first-page":"7160","DOI":"10.1073\/pnas.1705154114","volume":"114","author":"A Alon","year":"2017","unstructured":"Alon A, Schmidt HR, Wood MD, Sahn JJ, Martin SF, Kruse AC. Identification of the gene that codes for the \u03c3 2 receptor. Proc Natl Acad Sci. 2017;114(27):7160\u20135 Available from: http:\/\/www.pnas.org\/lookup\/doi\/10.1073\/pnas.1705154114.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"588_CR58","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/ncomms1386","volume":"2","author":"J Xu","year":"2011","unstructured":"Xu J, Zeng C, Chu W, Pan F, Rothfuss JM, Zhang F, et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun. 2011;2(2):380 [cited 2014 May 12]. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3624020&tool=pmcentrez&rendertype=abstract.","journal-title":"Nat Commun"},{"issue":"1","key":"588_CR59","doi-asserted-by":"publisher","first-page":"16845","DOI":"10.1038\/s41598-018-35430-3","volume":"8","author":"A Riad","year":"2018","unstructured":"Riad A, Zeng C, Weng C-C, Winters H, Xu K, Makvandi M, et al. Sigma-2 receptor\/TMEM97 and PGRMC-1 increase the rate of internalization of LDL by LDL receptor through the formation of a ternary complex. Sci Rep. 2018;8(1):16845 Available from: http:\/\/www.nature.com\/articles\/s41598-018-35430-3.","journal-title":"Sci Rep"},{"issue":"5","key":"588_CR60","doi-asserted-by":"publisher","first-page":"a024075","DOI":"10.1101\/cshperspect.a024075","volume":"7","author":"LM Smith","year":"2017","unstructured":"Smith LM, Strittmatter SM. Binding sites for amyloid-\u03b2 oligomers and synaptic toxicity. Cold Spring Harb Perspect Med. 2017;7(5):a024075 Available from: http:\/\/perspectivesinmedicine.cshlp.org\/lookup\/doi\/10.1101\/cshperspect.a024075.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7328","key":"588_CR61","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature09635","volume":"469","author":"M Ciss\u00e9","year":"2011","unstructured":"Ciss\u00e9 M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature. 2011;469(7328):47\u201352 [cited 2014 May 1]. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3030448&tool=pmcentrez&rendertype=abstract.","journal-title":"Nature"},{"issue":"11","key":"588_CR62","doi-asserted-by":"publisher","first-page":"e111898","DOI":"10.1371\/journal.pone.0111898","volume":"9","author":"NJ Izzo","year":"2014","unstructured":"Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, et al. Alzheimer\u2019s therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. PLoS One. 2014;9(11):e111898 Public Library of Science; [cited 2014 Nov 17]. Available from: http:\/\/dx.plos.org\/10.1371\/journal.pone.0111898.","journal-title":"PLoS One"},{"issue":"11","key":"588_CR63","doi-asserted-by":"publisher","first-page":"e111899","DOI":"10.1371\/journal.pone.0111899","volume":"9","author":"NJ Izzo","year":"2014","unstructured":"Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, et al. Alzheimer\u2019s therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2\/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS One. 2014;9(11):e111899 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25390692.","journal-title":"PLoS One"},{"key":"588_CR64","first-page":"20","volume":"5","author":"M Grundman","year":"2019","unstructured":"Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, et al. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer\u2019s disease. Alzheimer\u2019s Dement (New York, N Y). 2019;5:20\u20136 Available from: https:\/\/doi.org\/10.1016\/j.trci.2018.11.001.","journal-title":"Alzheimer\u2019s Dement (New York, N Y)"},{"issue":"5918","key":"588_CR65","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1126\/science.1169096","volume":"323","author":"KV Kuchibhotla","year":"2009","unstructured":"Kuchibhotla KV, Lattarulo CR, Hyman BT, Bacskai BJ. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science. 2009;323(5918):1211\u20135 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19251629.","journal-title":"Science"},{"issue":"5896","key":"588_CR66","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1126\/science.1162844","volume":"321","author":"MA Busche","year":"2008","unstructured":"Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold K-H, Haass C, et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer\u2019s disease. Science. 2008;321(5896):1686\u20139 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18802001.","journal-title":"Science"},{"issue":"1","key":"588_CR67","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ana.410410106","volume":"41","author":"T Gomez-Isla","year":"1997","unstructured":"Gomez-Isla T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer\u2019s disease. Ann Neurol. 1997;41(1):17\u201324.","journal-title":"Ann Neurol"},{"issue":"5","key":"588_CR68","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.2353\/ajpath.2006.050840","volume":"168","author":"TL Spires","year":"2006","unstructured":"Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, Ashe KH, et al. Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol. 2006;168(5):1598\u2013607.","journal-title":"Am J Pathol"},{"issue":"5733","key":"588_CR69","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1126\/science.1113694","volume":"309","author":"K Santa Cruz","year":"2005","unstructured":"Santa Cruz K. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309(5733):476\u201381 Available from: http:\/\/www.sciencemag.org\/cgi\/doi\/10.1126\/science.1113694.","journal-title":"Science"},{"issue":"34","key":"588_CR70","doi-asserted-by":"publisher","first-page":"10741","DOI":"10.1523\/JNEUROSCI.1065-09.2009","volume":"29","author":"M Polydoro","year":"2009","unstructured":"Polydoro M, Acker CM, Duff K, Castillo PE, Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci. 2009;29(34):10741\u20139 Available from: http:\/\/www.jneurosci.org\/cgi\/doi\/10.1523\/JNEUROSCI.1065-09.2009.","journal-title":"J Neurosci"},{"issue":"21","key":"588_CR71","doi-asserted-by":"publisher","first-page":"9340","DOI":"10.1523\/JNEUROSCI.22-21-09340.2002","volume":"22","author":"B Allen","year":"2002","unstructured":"Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002;22(21):9340\u201351 Available from: isi:000175724500174.","journal-title":"J Neurosci"},{"key":"588_CR72","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/978-1-4939-7704-8_23","volume":"1750","author":"MA Busche","year":"2018","unstructured":"Busche MA. In vivo two-photon calcium imaging of hippocampal neurons in Alzheimer mouse models. Methods Mol Biol. 2018;1750:341\u201351 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29512084.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"588_CR73","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41593-018-0298-7","volume":"22","author":"H Fu","year":"2019","unstructured":"Fu H, Possenti A, Freer R, Nakano Y, Villegas NCH, Tang M, et al. A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. Nat Neurosci. 2019;22(1):47\u201356 Available from: https:\/\/doi.org\/10.1038\/s41593-018-0298-7.","journal-title":"Nat Neurosci"},{"issue":"5","key":"588_CR74","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.neuron.2015.01.025","volume":"85","author":"N Menkes-Caspi","year":"2015","unstructured":"Menkes-Caspi N, Yamin HG, Kellner V, Spires-Jones TL, Cohen D, Stern EA. Pathological tau disrupts ongoing network activity. Neuron. 2015;85(5):959\u201366. Available from:. https:\/\/doi.org\/10.1016\/j.neuron.2015.01.025.","journal-title":"Neuron"},{"issue":"5","key":"588_CR75","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00401-011-0877-0","volume":"122","author":"JL Crimins","year":"2011","unstructured":"Crimins JL, Rocher AB, Peters A, Shultz P, Lewis J, Luebke JI. Homeostatic responses by surviving cortical pyramidal cells in neurodegenerative tauopathy. Acta Neuropathol. 2011;122(5):551\u201364.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"588_CR76","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.expneurol.2009.07.029","volume":"223","author":"AB Rocher","year":"2010","unstructured":"Rocher AB, Crimins JL, Amatrudo JM, Kinson MS, Todd-Brown MA, Lewis J, et al. Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp Neurol [Internet]. 2010;223(2):385\u201393 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488609003100.","journal-title":"Exp Neurol [Internet]"},{"issue":"3","key":"588_CR77","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","volume":"53","author":"Y Yoshiyama","year":"2007","unstructured":"Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TCC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337\u201351.","journal-title":"Neuron."},{"key":"588_CR78","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.nbd.2017.05.003","volume":"105","author":"MA Sealey","year":"2017","unstructured":"Sealey MA, Vourkou E, Cowan CM, Bossing T, Quraishe S, Grammenoudi S, et al. Distinct phenotypes of three-repeat and four-repeat human tau in a transgenic model of tauopathy. Neurobiol Dis. 2017;105:74\u201383.","journal-title":"Neurobiol Dis"},{"issue":"11","key":"588_CR79","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/pro.3499","volume":"27","author":"G Ghag","year":"2018","unstructured":"Ghag G, Bhatt N, Cantu DV, Guerrero-Munoz MJ, Ellsworth A, Sengupta U, et al. Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross-seeding behavior. Protein Sci. 2018;27(11):1901\u20139.","journal-title":"Protein Sci"},{"issue":"3","key":"588_CR80","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2478\/s13380-012-0032-y","volume":"3","author":"KJ Kopeikina","year":"2012","unstructured":"Kopeikina KJ, Hyman BT, Spires-Jones TL. Soluble forms of tau are toxic in Alzheimer\u2019s disease. Transl Neurosci. 2012;3(3):223\u201333 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23029602.","journal-title":"Transl Neurosci"},{"issue":"4","key":"588_CR81","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.ajpath.2011.07.004","volume":"179","author":"KJ Kopeikina","year":"2011","unstructured":"Kopeikina KJ, Carlson GA, Pitstick R, Ludvigson AE, Peters A, Luebke JI, et al. Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer\u2019s disease brain. Am J Pathol. 2011;179(4):2071\u201382. Available from:. https:\/\/doi.org\/10.1016\/j.ajpath.2011.07.004.","journal-title":"Am J Pathol"},{"issue":"5","key":"588_CR82","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00401-018-1903-2","volume":"136","author":"EK Pickett","year":"2018","unstructured":"Pickett EK, Rose J, McCrory C, McKenzie CA, King D, Smith C, et al. Region-specific depletion of synaptic mitochondria in the brains of patients with Alzheimer\u2019s disease. Acta Neuropathol. 2018;136(5):747\u201357 Available from: https:\/\/doi.org\/10.1007\/s00401-018-1903-2.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"588_CR83","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neuron.2018.06.003","volume":"99","author":"A Ittner","year":"2018","unstructured":"Ittner A, Ittner LM. Dendritic tau in Alzheimer\u2019s disease. Neuron. 2018;99(1):13\u201327 Available from: https:\/\/doi.org\/10.1016\/j.neuron.2018.06.003.","journal-title":"Neuron"},{"issue":"4","key":"588_CR84","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.neuron.2018.01.022","volume":"97","author":"J McInnes","year":"2018","unstructured":"McInnes J, Wierda K, Snellinx A, Bounti L, Wang YC, Stancu IC, et al. Synaptogyrin-3 mediates presynaptic dysfunction induced by tau. Neuron. 2018;97(4):823\u2013835.e8.","journal-title":"Neuron"},{"issue":"May","key":"588_CR85","doi-asserted-by":"publisher","first-page":"15295","DOI":"10.1038\/ncomms15295","volume":"8","author":"L Zhou","year":"2017","unstructured":"Zhou L, McInnes J, Wierda K, Holt M, Herrmann AG, Jackson RJ, et al. Tau association with synaptic vesicles causes presynaptic dysfunction. Nat Commun. 2017;8(May):15295 Available from: http:\/\/www.nature.com\/doifinder\/10.1038\/ncomms15295.","journal-title":"Nat Commun"},{"issue":"4","key":"588_CR86","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.ajpath.2012.06.033","volume":"181","author":"H Tai","year":"2012","unstructured":"Tai H, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol. 2012;181(4):1426\u201335 [cited 2014 May 20]. Available from: https:\/\/doi.org\/10.1016\/j.ajpath.2012.06.033.","journal-title":"Am J Pathol"},{"issue":"1","key":"588_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2051-5960-2-1","volume":"2","author":"HC Tai","year":"2014","unstructured":"Tai HC, Wang BY, Serrano-Pozo A, Frosch MP, Spires-Jones TL, Hyman BT. Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer\u2019s disease. Acta Neuropathol Commun. 2014;2(1):1\u201314.","journal-title":"Acta Neuropathol Commun"},{"key":"588_CR88","doi-asserted-by":"crossref","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8(6):595\u2013608. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27025652.","DOI":"10.15252\/emmm.201606210"},{"issue":"3","key":"588_CR89","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","volume":"142","author":"LM Ittner","year":"2010","unstructured":"Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-\u03b2 toxicity in Alzheimer\u2019s disease mouse models. Cell. 2010;142(3):387\u201397.","journal-title":"Cell"},{"issue":"2","key":"588_CR90","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1523\/JNEUROSCI.4152-10.2011","volume":"31","author":"ED Roberson","year":"2011","unstructured":"Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, et al. Amyloid-\/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer\u2019s disease. J Neurosci. 2011;31(2):700\u201311 Available from: http:\/\/www.jneurosci.org\/cgi\/doi\/10.1523\/JNEUROSCI.4152-10.2011.","journal-title":"J Neurosci"},{"issue":"5825","key":"588_CR91","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1126\/science.1141736","volume":"316","author":"ED Roberson","year":"2007","unstructured":"Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid -induced deficits in an Alzheimer\u2019s disease mouse model. Science. 2007;316(5825):750\u20134 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17478722.","journal-title":"Science"},{"issue":"5","key":"588_CR92","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1523\/JNEUROSCI.2610-10.2011","volume":"31","author":"OA Shipton","year":"2011","unstructured":"Shipton OA, Leitz JR, Dworzak J, Acton CEJ, Tunbridge EM, Denk F, et al. Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci. 2011;31(5):1688\u201392 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21289177.","journal-title":"J Neurosci"},{"issue":"2","key":"588_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41583-018-0113-1","volume":"20","author":"CM Henstridge","year":"2019","unstructured":"Henstridge CM, Hyman BT, Spires-Jones TL. Beyond the neuron\u2013cellular interactions early in Alzheimer disease pathogenesis. Nat Rev Neurosci. 2019;20(2):1 Available from: http:\/\/www.nature.com\/articles\/s41583-018-0113-1.","journal-title":"Nat Rev Neurosci"},{"issue":"5123","key":"588_CR94","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261(5123):921\u20133 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8346443.","journal-title":"Science"},{"issue":"7","key":"588_CR95","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell. 2017;169(7):1276\u20131290.e17 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28602351.","journal-title":"Cell"},{"issue":"212","key":"588_CR96","doi-asserted-by":"publisher","first-page":"212ra161","DOI":"10.1126\/scitranslmed.3007000","volume":"5","author":"E Hudry","year":"2013","unstructured":"Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T, et al. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med. 2013;5(212):212ra161 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24259049.","journal-title":"Sci Transl Med"},{"issue":"1","key":"588_CR97","doi-asserted-by":"publisher","first-page":"e201900325","DOI":"10.26508\/lsa.201900325","volume":"2","author":"E Hudry","year":"2019","unstructured":"Hudry E, Klickstein J, Cannavo C, Jackson R, Muzikansky A, Gandhi S, et al. Opposing roles of apolipoprotein E in aging and neurodegeneration. Life Sci Alliance. 2019;2(1):e201900325 Available from: http:\/\/www.life-science-alliance.org\/lookup\/doi\/10.26508\/lsa.201900325.","journal-title":"Life Sci Alliance"},{"issue":"6286","key":"588_CR98","first-page":"1","volume":"8373","author":"S Hong","year":"2016","unstructured":"Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;8373(6286):1\u20139 Available from: http:\/\/www.sciencemag.org\/cgi\/doi\/10.1126\/science.aad8373.","journal-title":"Science"},{"key":"588_CR99","doi-asserted-by":"crossref","unstructured":"Shi Q, Chowdhury S, Ma R, Le KX, Hong S, Caldarone BJ, et al. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP\/PS1 mice. Sci Transl Med. 2017;9(392):eaaf6295. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28566429.","DOI":"10.1126\/scitranslmed.aaf6295"},{"issue":"6","key":"588_CR100","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.neuron.2018.12.003","volume":"100","author":"C Davies","year":"2018","unstructured":"Davies C, Spires-Jones TL. Complementing tau: new data show that the complement system is involved in degeneration in tauopathies. Neuron. 2018;100(6):1267\u20139 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30571935.","journal-title":"Neuron"},{"issue":"6","key":"588_CR101","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.neuron.2018.10.031","volume":"100","author":"A Litvinchuk","year":"2018","unstructured":"Litvinchuk A, Wan Y-W, Swartzlander DB, Chen F, Cole A, Propson NE, et al. Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer\u2019s disease. Neuron. 2018;100(6):1337\u20131353.e5 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30415998.","journal-title":"Neuron"},{"issue":"6","key":"588_CR102","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.neuron.2018.10.014","volume":"100","author":"B Dejanovic","year":"2018","unstructured":"Dejanovic B, Huntley MA, De Mazi\u00e8re A, Meilandt WJ, Wu T, Srinivasan K, et al. Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies. Neuron. 2018;100(6):1322\u20131336.e7 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30392797.","journal-title":"Neuron"},{"issue":"2","key":"588_CR103","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.nbd.2008.10.011","volume":"33","author":"TL Spires-Jones","year":"2009","unstructured":"Spires-Jones TL, Mielke ML, Rozkalne A, Meyer-Luehmann M, de Calignon A, Bacskai BJ, et al. Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol Dis. 2009;33(2):213\u201320 [cited 2014 May 21]. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=2672591&tool=pmcentrez&rendertype=abstract.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"588_CR104","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12031-011-9604-5","volume":"45","author":"A Sydow","year":"2011","unstructured":"Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, et al. Reversibility of Tau-related cognitive defects in a regulatable FTD mouse model. J Mol Neurosci. 2011;45(3):432\u20137 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21822709.","journal-title":"J Mol Neurosci"},{"issue":"7","key":"588_CR105","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1523\/JNEUROSCI.5245-10.2011","volume":"31","author":"A Sydow","year":"2011","unstructured":"Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, et al. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci. 2011;31(7):2511\u201325 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21325519.","journal-title":"J Neurosci"},{"key":"588_CR106","unstructured":"Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer\u2019s disease. Nature. 2000;408(6815):979\u201382. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11140685."},{"issue":"6740","key":"588_CR107","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173\u20137 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10408445.","journal-title":"Nature"},{"key":"588_CR108","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41541-018-0046-8","volume":"3","author":"A Bittar","year":"2018","unstructured":"Bittar A, Sengupta U, Kayed R. Prospects for strain-specific immunotherapy in Alzheimer\u2019s disease and tauopathies. NPJ vaccines. 2018;3:9 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29507776.","journal-title":"NPJ vaccines"},{"issue":"4","key":"588_CR109","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14(4):535\u201362 Available from: https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"2","key":"588_CR110","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/ageing\/afy167","volume":"48","author":"J McCleery","year":"2019","unstructured":"McCleery J, Flicker L, Richard E, Quinn TJ. When is Alzheimer\u2019s not dementia-Cochrane commentary on The National Institute on Ageing and Alzheimer\u2019s Association Research Framework for Alzheimer\u2019s Disease. Age Ageing. 2019;48(2):174\u20137 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30329009.","journal-title":"Age Ageing"},{"issue":"348","key":"588_CR111","doi-asserted-by":"publisher","first-page":"348ra96","DOI":"10.1126\/scitranslmed.aaf6667","volume":"8","author":"SJ Finnema","year":"2016","unstructured":"Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin S, Chen M, et al. Imaging synaptic density in the living human brain. Sci Transl Med. 2016;8(348):348ra96 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27440727.","journal-title":"Sci Transl Med"},{"issue":"3","key":"588_CR112","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11307-018-1260-5","volume":"21","author":"CC Constantinescu","year":"2019","unstructured":"Constantinescu CC, Tresse C, Zheng M, Gouasmat A, Carroll VM, Mistico L, et al. Development and in vivo preclinical imaging of fluorine-18-labeled synaptic vesicle protein 2A (SV2A) PET tracers. Mol Imaging Biol. 2019;21(3):509\u201318 Available from: http:\/\/link.springer.com\/10.1007\/s11307-018-1260-5.","journal-title":"Mol Imaging Biol"},{"issue":"3","key":"588_CR113","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1021\/acschemneuro.8b00526","volume":"10","author":"S Li","year":"2019","unstructured":"Li S, Cai Z, Wu X, Holden D, Pracitto R, Kapinos M, et al. Synthesis and in vivo evaluation of a novel PET radiotracer for imaging of synaptic vesicle glycoprotein 2A (SV2A) in nonhuman primates. ACS Chem Neurosci. 2019;10(3):1544\u201354 Available from: https:\/\/pubs.acs.org\/doi\/10.1021\/acschemneuro.8b00526.","journal-title":"ACS Chem Neurosci"},{"key":"588_CR114","first-page":"1","volume":"8042","author":"M-K Chen","year":"2018","unstructured":"Chen M-K, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin S, et al. Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. JAMA Neurol. 2018;8042:1\u201310 Available from: https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2687472?widget=personalizedcontent&previousarticle=2687466.","journal-title":"JAMA Neurol"},{"issue":"2","key":"588_CR115","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF02815094","volume":"27","author":"P Davidsson","year":"1996","unstructured":"Davidsson P, Jahn R, Bergquist J, Ekman R, Blennow K. Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer disease? Mol Chem Neuropathol. 1996;27(2):195\u2013210 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8962603.","journal-title":"Mol Chem Neuropathol"},{"issue":"3","key":"588_CR116","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/(SICI)1522-2683(19990301)20:3<431::AID-ELPS431>3.0.CO;2-2","volume":"20","author":"P Davidsson","year":"1999","unstructured":"Davidsson P, Puchades M, Blennow K. Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. Electrophoresis. 1999;20(3):431\u20137 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10217148.","journal-title":"Electrophoresis"},{"issue":"1","key":"588_CR117","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00401-018-1910-3","volume":"137","author":"H Kvartsberg","year":"2019","unstructured":"Kvartsberg H, Lashley T, Murray CE, Brinkmalm G, Cullen NC, H\u00f6glund K, et al. The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer\u2019s disease. Acta Neuropathol. 2019;137(1):89\u2013102 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30244311.","journal-title":"Acta Neuropathol"},{"key":"588_CR118","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.brainres.2010.09.073","volume":"1362","author":"A Thorsell","year":"2010","unstructured":"Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer\u2019s disease. Brain Res. 2010;1362:13\u201322. Available from:. https:\/\/doi.org\/10.1016\/j.brainres.2010.09.073.","journal-title":"Brain Res"},{"issue":"10","key":"588_CR119","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jalz.2014.10.009","volume":"11","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, \u00d6hrfelt A, Andersson K, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer\u2019s disease. Alzheimers Dement. 2015;11(10):1180\u201390 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25533203.","journal-title":"Alzheimers Dement"},{"issue":"Pt 11","key":"588_CR120","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1093\/brain\/awv267","volume":"138","author":"E Portelius","year":"2015","unstructured":"Portelius E, Zetterberg H, Skillb\u00e4ck T, T\u00f6rnqvist U, Andreasson U, Trojanowski JQ, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer\u2019s disease. Brain. 2015;138(Pt 11):3373\u201385 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26373605.","journal-title":"Brain"},{"issue":"5","key":"588_CR121","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","volume":"73","author":"R Tarawneh","year":"2016","unstructured":"Tarawneh R, D\u2019Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, et al. Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. JAMA Neurol. 2016;73(5):561\u201371 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27018940.","journal-title":"JAMA Neurol"},{"issue":"3","key":"588_CR122","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00401-018-1851-x","volume":"136","author":"E Portelius","year":"2018","unstructured":"Portelius E, Olsson B, H\u00f6glund K, Cullen NC, Kvartsberg H, Andreasson U, et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. 2018;136(3):363\u201376 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29700597.","journal-title":"Acta Neuropathol"},{"issue":"9","key":"588_CR123","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1212\/WNL.0000000000002423","volume":"86","author":"H Wellington","year":"2016","unstructured":"Wellington H, Paterson RW, Portelius E, T\u00f6rnqvist U, Magdalinou N, Fox NC, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86(9):829\u201335.","journal-title":"Neurology."},{"issue":"1","key":"588_CR124","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jalz.2018.08.006","volume":"15","author":"\u00c5 Sandelius","year":"2019","unstructured":"Sandelius \u00c5, Portelius E, K\u00e4ll\u00e9n \u00c5, Zetterberg H, Rot U, Olsson B, et al. Elevated CSF GAP-43 is Alzheimer\u2019s disease specific and associated with tau and amyloid pathology. Alzheimers Dement. 2019;15(1):55\u201364 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30321501.","journal-title":"Alzheimers Dement"},{"key":"588_CR125","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1750-1326-9-53","volume":"9","author":"A Brinkmalm","year":"2014","unstructured":"Brinkmalm A, Brinkmalm G, Honer WG, Fr\u00f6lich L, Hausner L, Minthon L, et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer\u2019s disease. Mol Neurodegener. 2014;9:53 Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=4253625&tool=pmcentrez&rendertype=abstract.","journal-title":"Mol Neurodegener"},{"key":"588_CR126","doi-asserted-by":"crossref","unstructured":"Rauchmann B-S, Sadlon A, Perneczky R. Alzheimer\u2019s disease neuroimaging initiative. Soluble TREM2 and inflammatory proteins in Alzheimer\u2019s disease cerebrospinal fluid. J Alzheimers Dis. 2020; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31958095.","DOI":"10.3233\/JAD-191120"},{"issue":"5","key":"588_CR127","doi-asserted-by":"publisher","first-page":"466","DOI":"10.15252\/emmm.201506123","volume":"8","author":"M Su\u00e1rez-Calvet","year":"2016","unstructured":"Su\u00e1rez-Calvet M, Kleinberger G, Araque Caballero M\u00c1, Brendel M, Rominger A, Alcolea D, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer\u2019s disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8(5):466\u201376 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26941262.","journal-title":"EMBO Mol Med"},{"issue":"6","key":"588_CR128","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00401-016-1533-5","volume":"131","author":"L Piccio","year":"2016","unstructured":"Piccio L, Deming Y, Del-\u00c1guila JL, Ghezzi L, Holtzman DM, Fagan AM, et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131(6):925\u201333 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26754641.","journal-title":"Acta Neuropathol"},{"key":"588_CR129","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-016-0071-x","volume":"11","author":"A Heslegrave","year":"2016","unstructured":"Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer\u2019s disease. Mol Neurodegener. 2016;11:3 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26754172.","journal-title":"Mol Neurodegener"},{"key":"588_CR130","doi-asserted-by":"crossref","unstructured":"Lashley T, Schott JM, Weston P, Murray CE, Wellington H, Keshavan A, et al. Molecular biomarkers of Alzheimer\u2019s disease: progress and prospects. Dis Model Mech. 2018;11(5):dmm031781. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29739861.","DOI":"10.1242\/dmm.031781"},{"issue":"3","key":"588_CR131","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1074\/mcp.RA118.001290","volume":"18","author":"A Lle\u00f3","year":"2019","unstructured":"Lle\u00f3 A, N\u00fa\u00f1ez-Llaves R, Alcolea D, Chiva C, Balateu-Pa\u00f1os D, Colom-Cadena M, et al. Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer\u2019s disease cerebrospinal fluid. Mol Cell Proteomics. 2019;18(3):546\u201360 Available from: http:\/\/www.mcponline.org\/lookup\/doi\/10.1074\/mcp. RA118.001290.","journal-title":"Mol Cell Proteomics"},{"key":"588_CR132","doi-asserted-by":"crossref","unstructured":"Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol Med. 2019;11(12):dmm031781. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.15252\/emmm.201911170.","DOI":"10.15252\/emmm.201911170"},{"key":"588_CR133","first-page":"63","volume":"3","author":"CN Winston","year":"2016","unstructured":"Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, et al. Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimer\u2019s Dement (Amsterdam, Netherlands). 2016;3:63\u201372 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27408937.","journal-title":"Alzheimer\u2019s Dement (Amsterdam, Netherlands)"},{"issue":"OCT","key":"588_CR134","first-page":"1","volume":"5","author":"SS Poil","year":"2013","unstructured":"Poil SS, de Haan W, van der Flier WM, Mansvelder HD, Scheltens P, Linkenkaer-Hansen K. Integrative EEG biomarkers predict progression to Alzheimer\u2019s disease at the MCI stage. Front Aging Neurosci. 2013;5(OCT):1\u201312.","journal-title":"Front Aging Neurosci"},{"issue":"JUL","key":"588_CR135","first-page":"1","volume":"10","author":"JJ van der Zande","year":"2018","unstructured":"van der Zande JJ, Gouw AA, van Steenoven I, Scheltens P, Stam CJ, Lemstra AW. EEG characteristics of dementia with Lewy bodies, Alzheimer\u2019s disease and mixed pathology. Front Aging Neurosci. 2018;10(JUL):1\u201310.","journal-title":"Front Aging Neurosci"},{"key":"588_CR136","volume-title":"Niedermeyer\u2019s electroencephalography. Basic principles, clinical applications, and related fields","author":"DL Schomer","year":"2010","unstructured":"Schomer DL, da Silva FL. Niedermeyer\u2019s electroencephalography. Basic principles, clinical applications, and related fields. 6th ed. Philadelphia: Lippincott Wiliams & Wilkins; 2010.","edition":"6"},{"issue":"5","key":"588_CR137","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1046\/j.1468-1331.2003.00643.x","volume":"10","author":"JS Ebersole","year":"2003","unstructured":"Ebersole JS, Pedley TA. Current practice of clinical electroencephalography, 3rd edn. Eur J Neurol. 2003;10(5):604\u20135. Available from. https:\/\/doi.org\/10.1046\/j.1468-1331.2003.00643.x.","journal-title":"Eur J Neurol"},{"issue":"7","key":"588_CR138","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.clinph.2004.01.001","volume":"115","author":"J Jeong","year":"2004","unstructured":"Jeong J. EEG dynamics in patients with Alzheimer\u2019s disease. Clin Neurophysiol. 2004;115(7):1490\u2013505 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15203050.","journal-title":"Clin Neurophysiol"},{"issue":"October","key":"588_CR139","doi-asserted-by":"publisher","first-page":"102046","DOI":"10.1016\/j.nicl.2019.102046","volume":"24","author":"U Smailovic","year":"2019","unstructured":"Smailovic U, Koenig T, Laukka EJ, Kalpouzos G, Andersson T, Winblad B, et al. EEG time signature in Alzheimer\u2019s disease: functional brain networks falling apart. NeuroImage Clin. 2019;24(October):102046 Available from: https:\/\/doi.org\/10.1016\/j.nicl.2019.102046.","journal-title":"NeuroImage Clin"},{"key":"588_CR140","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.neurobiolaging.2017.11.005","volume":"63","author":"U Smailovic","year":"2018","unstructured":"Smailovic U, Koenig T, K\u00e5reholt I, Andersson T, Kramberger MG, Winblad B, et al. Quantitative EEG power and synchronization correlate with Alzheimer\u2019s disease CSF biomarkers. Neurobiol Aging. 2018;63:88\u201395. Available from. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.11.005.","journal-title":"Neurobiol Aging"},{"key":"588_CR141","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.neurobiolaging.2017.05.017","volume":"57","author":"AA Gouw","year":"2017","unstructured":"Gouw AA, Alsema AM, Tijms BM, Borta A, Scheltens P, Stam CJ, et al. EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. Neurobiol Aging. 2017;57:133\u201342 Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458017301847.","journal-title":"Neurobiol Aging"},{"issue":"3","key":"588_CR142","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00213-008-1111-1","volume":"198","author":"LRR Gianotti","year":"2008","unstructured":"Gianotti LRR, K\u00fcnig G, Faber PL, Lehmann D, Pascual-Marqui RD, Kochi K, et al. Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer\u2019s disease. Psychopharmacology (Berl). 2008;198(3):323\u201332 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18446328.","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"588_CR143","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000054902","volume":"43","author":"G Adler","year":"2001","unstructured":"Adler G, Brassen S. Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients. Neuropsychobiology. 2001 Jan;43(4):273\u20136.","journal-title":"Neuropsychobiology."},{"key":"588_CR144","first-page":"292","volume":"75","author":"G Adler","year":"2004","unstructured":"Adler G, Brassen S, Chwalek K, Dieter B, Teufel M. Prediction of treatment response to rivastigmine in Alzheimer\u2019s dementia. J Neurol Neurosurg Psychiatry. 2004;75:292\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"July","key":"588_CR145","first-page":"179","volume":"6","author":"DV Moretti","year":"2014","unstructured":"Moretti DV, Frisoni GB, Binetti G, Zanetti O. Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer\u2019s disease. Front Aging Neurosci. 2014;6(July):179.","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"588_CR146","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1055\/s-2003-45118","volume":"36","author":"S Brassen","year":"2003","unstructured":"Brassen S, Adler G. Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial. Pharmacopsychiatry. 2003;36(6):304\u20138 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14663655.","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"588_CR147","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.clinph.2012.09.017","volume":"124","author":"C Babiloni","year":"2013","unstructured":"Babiloni C, Del Percio C, Bordet R, Bourriez J-L, Bentivoglio M, Payoux P, et al. Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer\u2019s disease patients. Clin Neurophysiol. 2013;124(5):837\u201350 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23098644.","journal-title":"Clin Neurophysiol"},{"issue":"1","key":"588_CR148","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3233\/JAD-2012-121189","volume":"31","author":"P Scheltens","year":"2012","unstructured":"Scheltens P, Twisk JWR, Blesa R, Scarpini E, von Arnim CAF, Bongers A, et al. Efficacy of Souvenaid in mild Alzheimer\u2019s disease: results from a randomized, controlled trial. J Alzheimers Dis. 2012 Jan;31(1):225\u201336.","journal-title":"J Alzheimers Dis"},{"key":"588_CR149","doi-asserted-by":"crossref","unstructured":"Scheltens P, Hallikainen M, Grimmer T, Duning T, Alida G, Teunissen C, et al. Safety, tolerability and efficacy of the glutaminyl-cyclase inhibitor PQ912 in Alzheimer\u2019s disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimers Res Ther. 2018;10(1):107.","DOI":"10.1186\/s13195-018-0431-6"},{"issue":"9","key":"588_CR150","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13195-014-0086-x","volume":"6","author":"EC van Straaten","year":"2014","unstructured":"van Straaten EC, Scheltens P, Gouw AA, Stam CJ. Eyes-closed task-free electroencephalography in clinical trials for Alzheimer\u2019s disease: an emerging method based upon brain dynamics. Alzheimers Res Ther. 2014;6(9):86.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"588_CR151","doi-asserted-by":"publisher","first-page":"e86558","DOI":"10.1371\/journal.pone.0086558","volume":"9","author":"H de Waal","year":"2014","unstructured":"de Waal H, Stam CJJ, Lansbergen MMM, Wieggers RLL, Kamphuis PJGHJGH, Scheltens P, et al. The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer\u2019s disease: a randomised controlled study. PLoS One. 2014;9(1):e86558 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24475144.","journal-title":"PLoS One"},{"issue":"12","key":"588_CR152","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0166-2236(02)02264-6","volume":"25","author":"D Attwell","year":"2002","unstructured":"Attwell D, Iadecola C. The neural basis of functional brain imaging signals. Trends Neurosci. 2002;25(12):621\u20135 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12446129.","journal-title":"Trends Neurosci"},{"key":"588_CR153","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1196\/annals.1427.007","volume":"1147","author":"L Mosconi","year":"2008","unstructured":"Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer\u2019s disease. Ann N Y Acad Sci. 2008;1147:180\u201395 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19076441.","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"588_CR154","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","volume":"32","author":"SM Landau","year":"2011","unstructured":"Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7):1207\u201318 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19660834.","journal-title":"Neurobiol Aging"},{"issue":"3","key":"588_CR155","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jalz.2010.03.003","volume":"6","author":"WJ Jagust","year":"2010","unstructured":"Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer\u2019s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010;6(3):221\u20139 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20451870.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"588_CR156","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21514248.","journal-title":"Alzheimers Dement"},{"key":"588_CR157","doi-asserted-by":"crossref","unstructured":"van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, et al. Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2019; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31329216.","DOI":"10.1001\/jamaneurol.2019.2050"},{"key":"588_CR158","unstructured":"Harrison JE, Maruff P, Schembri A, Novak P, Ondrus M, Prenn-gologranc C, Katina S. Stability, reliability, validity and relationship to biomarkers of the BRADER \u2013 a new assessment for capturing cognitive changes in patients with Alzheimer\u2019s disease. Alzheimers Res Ther."},{"issue":"1","key":"588_CR159","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13195-018-0386-7","volume":"10","author":"JE Harrison","year":"2018","unstructured":"Harrison JE. Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer\u2019s disease. Alzheimers Res Ther. 2018;10(1):61 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29958538.","journal-title":"Alzheimers Res Ther"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00588-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-020-00588-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00588-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T08:28:14Z","timestamp":1722500894000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00588-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":159,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["588"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00588-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,2]]},"assertion":[{"value":"27 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Figure\u00a0\n                      \n                      was produced using human tissue obtained from the Edinburgh MRC Sudden death Brain Bank. The use of human tissue for post-mortem studies has been reviewed and approved by the Edinburgh Brain Bank ethics committee and the ACCORD medical research ethics committee (approval number 15-HV-016; ACCORD is the Academic and Clinical Central Office for Research and Development, a joint office of the University of Edinburgh and NHS Lothian). The Edinburgh Brain Bank is a Medical Research Council-funded facility with research ethics committee (REC) approval (11\/ES\/0022).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Anthony Caggiano, Nicholas Izzo, and Susan Catalano are employees or have financial interest in Cognition Therapeutics, Inc. Henrik Zetterberg has served at scientific advisory boards for Cognition Therapeutics, Roche Diagnostics, Wave and Samumed; has given lectures in symposia sponsored by Biogen and Alzecure; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Tara Spires-Jones is a scientific advisory board member of Cognition Therapeutics and receives collaborative grant funding from two pharmaceutical companies. John Harrison has received consultancy payments and honoraria from the following organizations in the past 2\u2009years: 23andMe, Alzecure, Aptinyx, Athira Pharma, Axon Neuroscience, Axovant, Biogen, Boehringer Ingelheim, CRF Bracket, Cognition Therapeutics, Compass Therapeutics, Curasen, DeNDRoN, EIP Pharma, Eisai, Eli Lilly, GfHEu, Heptares, Johnson & Johnson, Lundbeck, Lysosome Therapeutics, Merck, Neurodyn, Neurotrack, Novartis, Nutricia, Probiodrug, Regeneron, Rodin Therapeutics, Roivant, Sanofi, Takeda, vTv Therapeutics, and Winterlight Labs. Kaj Blennow has served as a consultant or at advisory boards for Alector, Biogen, Cognition Therapeutics, Lilly, MagQu, Novartis, and Roche Diagnostics and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Christopher van Dyck has served as a consultant or scientific advisor in the past 2\u2009years for Roche, Eisai, and Kyowa Kirin and received grant support for clinical trials from Roche, Genentech, Eisai, Biogen, Eli Lilly, Novartis, Merck, Biohaven, and Janssen. Lon Schneider reports grants and personal fees from Eli Lilly, personal fees from Avraham, Ltd., personal fees from Boehringer Ingelheim, grants and personal fees from Merck, personal fees from Neurim, Ltd., personal fees from Neuronix, Ltd., personal fees from Cognition Therapeutics, personal fees from Eisai, personal fees from Takeda, personal fees from vTv, grants and personal fees from Roche\/Genentech, grants from Biogen, grants from Novartis, personal fees from Abbott, and grants from Biohaven, outside the submitted work. Philip Scheltens reports consultancies with Axon Neuroscience, Cognition Therapeutics, Vivoryon, and Novartis, as well as a DSMB membership with Genentech. Michael Grundman is a paid consultant to Cognition Therapeutics. Howard Fillit has been a consultant to Axovant, vTv, Lundbeck, Otsuka, Lilly, Biogen (RTI), Roche, Genentech, Merck, Samus, Pfizer, and Alector in the past 5\u00a0years and has no conflicts that are related to this manuscript. Steven T. DeKosky is a member of the Neuroscience Advisory Board for Amgen, Chair of the Medical Scientific Advisory Board for Acumen, Chair of the Drug Monitoring Committee for Biogen, Chair of the Medical Advisory Board for Cognition Therapeutics, and Editor for Dementia for UpToDate. Mart\u00ed Colom Cadena and Willem de haan declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}